Geron (GERN) Shares Outstanding (2010 - 2026)
Geron (GERN) posted Shares Outstanding (Entity) of $669375.0 for Q1 2026, down 99.9% sequentially from $639.9 million in Q4 2025, and down 99.89% YoY from $636.9 million in Q1 2025.
Geron (GERN) Shares Outstanding (2010 - 2026) Analysis & Trends
Geron has reported Shares Outstanding (Entity) for 17 years, with the latest figure at $669375.0 in Q1 2026.
- Quarterly Shares Outstanding (Entity) fell 99.89% year-over-year to $669375.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $669375.0 (down 99.89% YoY) and the FY2025 annual result came in at $639.9 million, up 5.52% from the prior year.
- Shares Outstanding (Entity) declined to $669375.0 in Q1 2026 per GERN's latest filing, from $639.9 million in the prior quarter.
- Over five years, Shares Outstanding (Entity) peaked at $639.9 million in Q4 2025 and troughed at $669375.0 in Q1 2026.
- A 5-year average of $506.3 million and a median of $544.9 million in 2023 frame the typical range for Shares Outstanding (Entity).
- The sharpest annual moves came in 2023 and 2026: Shares Outstanding (Entity) jumped 42.45% in 2023, then tumbled 99.89% in 2026.
- Over 5 years, Shares Outstanding (Entity) stood at $390.3 million in 2022, then soared by 39.63% to $544.9 million in 2023, then climbed by 11.28% to $606.4 million in 2024, then advanced by 5.52% to $639.9 million in 2025, then tumbled by 99.9% to $669375.0 in 2026.
- According to Business Quant data, Shares Outstanding (Entity) over the past three periods registered $669375.0, $639.9 million, and $638.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 62.19 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 398.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 111.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 133.61 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 241.70 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 217.35 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 445.06 Mn |
| 10 | Geron | 1.02 Mn | -299.83 Mn | - | 670,696.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 670,696.00 |
| Mar 31, 2026 | 669,375.00 |
| Dec 31, 2025 | 666.66 Mn |
| Sep 30, 2025 | 667.10 Mn |
| Jun 30, 2025 | 666.17 Mn |
| Mar 31, 2025 | 665.91 Mn |
| Dec 31, 2024 | 646.03 Mn |
| Sep 30, 2024 | 662.16 Mn |
| Jun 30, 2024 | 653.90 Mn |
| Mar 31, 2024 | 603.49 Mn |
| Dec 31, 2023 | 570.65 Mn |
| Sep 30, 2023 | 579.51 Mn |
| Jun 30, 2023 | 547.28 Mn |
| Mar 31, 2023 | 544.46 Mn |
| Dec 31, 2022 | 380.78 Mn |
| Sep 30, 2022 | 405.24 Mn |
| Jun 30, 2022 | 403.87 Mn |
| Mar 31, 2022 | 332.07 Mn |
| Dec 31, 2021 | 327.63 Mn |
| Sep 30, 2021 | 328.93 Mn |